BioMedWire Stocks

20 States File Lawsuit Against Trump Administration for Releasing Medicaid Data to DHS

Rob Bonta, the Attorney General of California, revealed on Tuesday that 20 states have filed a lawsuit challenging the federal government’s release of private Medicaid data to deportation personnel in June. The shared data affects millions of people enrolled in Medicaid. 

Advisers to the HHS Secretary ordered CMS officials to release private data, including names, immigration status, social security numbers, addresses, as well as claims data by those enrollees in several jurisdictions, such as Washington State, Illinois, Washington, D.C., and California to the Department of Homeland Security (DHS). The states included in the data sharing request were selected because those states allow immigrants who haven’t regularized their stay to access Medicaid funded by revenue generated locally within the state. 

While announcing the filing of the lawsuit, Bonta said the federal administration had violated longstanding privacy laws protecting health information, such as HIPAA. The private health data shared can enable deportation officials to identify and locate individuals that are in the country illegally, and then deport them. 

Available information suggests that a plan was set in motion back in May to give federal authorities access to private Medicaid data from states that allow undocumented immigrants to access state government-funded Medicaid. At the time, CMS revealed that it would be conducting a review to ascertain that those states weren’t using federal funds to provide Medicaid to illegal immigrants. 

Consequently, CMS asked those states to share their Medicaid data for the review. Hardly a month later, HHS asked CMS to share that data with DHS. Despite back and forth email communication in which CMS officials explained why it would be illegal to share such information, HHS wrote to CMS ordering them to release the data by 5:30 ET on the very day (June 10) that directive was sent. 

HHS insists that its actions are within the law and that it is executing its mandate to ensure Medicaid benefits go to citizens and not non-citizens. The agency doesn’t explain how giving that information to DHS helps HHS to perform its role. 

It is against this backdrop that 20 states are suing over the matter. There is concern that the federal administration is willing to flout existing laws in order to attain its objectives, such as conducting mass deportations. 

The possibility that the private health data of their policyholders could one day be shared in violation of all laws protecting the privacy of this data must be causing firms like Astiva Health plenty of concern because such violations are unprecedented. 

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

What Patients Need to Know About Exercising During Cancer Treatment

It may sound strange to speak of exercising and cancer treatment in the same breath,…

23 hours ago

Senator Sanders Suggests Six Other Ways to Address Health Crisis

On Tuesday, Senator Bernie Sanders authored a letter that he sent to Democrats in both…

2 days ago

Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

BioMedWire Editorial Coverage: As late-stage biotech pipelines mature, fair-value remeasurements under U.S. Generally Accepted Accounting…

2 days ago

Parent Explains Why it is Wrong to Say Vaccines Cause Autism

For a while, the media has been filled with claims that vaccines cause autism. These…

4 days ago

Wegovy, Ozempic Could Reduce Deaths Resulting from Colon Cancer

A study that was recently published by a team of UC San Diego researchers has…

1 week ago

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Targets Glioblastoma with Innovative Therapies, Addressing One of Oncology’s Greatest Unmet Needs

Glioblastoma multiforme (“GBM”) is an aggressive brain cancer with limited treatment options, and CEO John…

1 week ago